Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen


Cite item

Full Text

Abstract

Aim. To implement in 2009—2012 the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen in patients with type 1 diabetes mellitus (DM) to evaluate the efficiency and safety of therapy with human insulin analogues. Subjects and methods. The program covered 100 patients aged 19 to 25 years from 7 regions of the Russian Federation, who had had DM onset at the age of 9—13 years, were using human recombinant insulins as continuous insulin therapy, and had glycated hemoglobin (HbA1c) levels of 7 to 9%. The main inclusion criterion was switching to insulin therapy with the human insulin analogues Lantus and Apidra. Results. A total 41 men and 59 women were followed up. Their mean baseline HbA1c level was 8.3±0.7%. After 24 months of therapy, HbA1c was significantly decreased to 7.7±0.7%; its change compared with that at Visit 1 was –0.6±0.6% (p<0.001). There was a significant reduction in fasting and postprandial blood glucose levels at 3 months of a follow-up. The number of symptomatic and asymptomatic glycemic episodes declined. No nocturnal or severe hypoglycemic episodes were recorded at 24 months of therapy. Microvascular complications did not progress during the follow-up. Conclusion. The use of human insulin analogues is effective and safe in treating young diabetic patients, improves their quality of life and confers no risk of asymptomatic or nocturnal hypoglycemic states.

References

  1. Сунцов Ю.И., Дедов И.И., Болотская Л.Л. Экономический эффект использования современных технологий в лечении сахарного диабета. Сахарный диабет. 2006;2:60-62.
  2. Arnett JJ. Emerging adulthood. A theory of development from the late teens through the twenties. Am Psychol. 2000;55:469-480.
  3. Anne Peters, Lori Laffel, and the American Diabetes Association Transitions Working Group. Diabetes Care for Emerging Adults: Recommendations for Transition From Pediatric to Adult Diabetes Care Systems. Diabetes Care. 2011;34(11):2477-2485.
  4. The diabetes control and complications trial research group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968-983.
  5. Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin of North Am. 1996;25:243-254 (Review).
  6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26:S18-S24.
  7. Cryer P, Childs BP. Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum. 2002;15:20-27.
  8. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev. 1999;15:42-46.
  9. Bolli GB. The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diabetes Res Clin Pract. 1989;6:S3-S16.
  10. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7:188-199.
  11. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitys: scintific review. JAMA. 2003;289(17):2254-2264.
  12. Riddle M, Rosenstock J, Gerich J, Investigators IGS. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care. 2003;26:3080-3086.
  13. Rosenstock J, Massi Benedetti M, Haring HU, Lin Z, Salzman A. Confirmed lower risk of hypoglycemia with insulin glargine versus NPH insulin: a meta-analysis of 2304 patients with type 2 diabetes. Diabetologia. 2003;46:A304.
  14. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes: HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-1136.
  15. American Diabetes Association: Clinical Practice Recommendations 2003. Diabetes Care. 2003;26 (Suppl.1):S1-S156.
  16. Urich H, Snyder B, Garg SK. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag. 2007;3:245-254.
  17. Garg S, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 2005;11:11-17.
  18. Petitti DB, Klingensmith GJ, Bell RA, Andrews JS, Dabelea D, Imperatore G, Marcovina S, Pihoker C, Standiford D, Waitzfelder B, Mayer-Davis E, SEARCH for Diabetes in Youth Study Group Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr. 2009;155:668-672, e1-e3.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies